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Background: Glucocorticoids commonly cause drug-induced diabetes. This association is well recognized but
available evidence does not answer clinically relevant issues in subjects without diabetes.
Methods: Thirty-five individuals without diabetes with a recent diagnosis of acute lymphoblastic leukemia or non-
Hodgkin’s lymphoma on high-dose glucocorticoid therapy were studied. Close systematic monitoring of fasting and
postprandial glycemia and fasting insulin determinations, HOMA-insulin resistance and HOMA β-cell function were
performed. The primary objective was to define the incidence of secondary diabetes in patients treated with high-
dose glucocorticoids. Secondary objectives were to specify the intensity, the moment it appears and the evolution
of hyperglycemia, in addition to the risk factors, mechanisms and impact of continuous and cyclical glucocorticoids
on the development of hyperglycemia.
Results: Mean age of patients was 38.4 ± 18.7 years. The incidence of diabetes was 40.6% and was found after the
first week; half the time it occurred between the second and fourth. Two-thirds spontaneously normalized by eight
weeks. Continuous glucocorticoid administration had a higher incidence of fasting hyperglycemia (P = 0.003). Mean
peak insulin levels were significantly higher in cases of diabetes.
Conclusions: High-dose prednisone for 2 to 3 months produced an elevated incidence of diabetes, usually with
mild hyperglycemia occurring between the second and fourth week, normalizing spontaneously in all cases.
Hyperglycemia was more frequent with continuous doses and occurred in cases with increased insulin resistance.
The clinical and therapeutic characteristics of our participants, who were otherwise healthy, could represent the
clinical setting of many patients with illness from other medical areas that might require high doses of GC for six to
twelve weeks.
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Drug-induced diabetesBackground
Drug-induced hyperglycemia is a clinical condition that
can occur as a result of impaired insulin secretion or ac-
tion or the destruction of pancreatic beta cells [1]. The ad-
ministration of glucocorticoids (GC) is a common cause
[2]. Gulliford et al. found 2% of newly diagnosed cases of
diabetes mellitus (DM) due to orally administered GC [3].* Correspondence: jgonzalezg@investigacion-meduanl.com
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distribution, and reproduction in any mediumIts use is associated with multiple side effects with DM be-
ing one of the most important [4,5]. In cases of DM prior
to the use of GC, worsening of glycemic control is typical;
however, in patients without DM, glucocorticoids may
transiently or permanently induce hyperglycemia [5-7].
Two mechanisms are predominantly responsible for
hyperglycemia secondary to GC: a decrease in insulin se-
cretion and insulin sensitivity [5,7,8]. Although the link
between GC and hyperglycemia was identified more
than 50 years ago, clinically relevant questions remain
unanswered [2,5,7,9]. The incidence of DM secondary to
the use of GC, the profile of subjects in whom it occurs,ed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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comes apparent, its intensity, and its evolution in the
short and medium term are not well defined. An inci-
dence of 2% to 50% has been reported [3,10]. Published
studies have used methodologies accountable for this
broad range. Most are retrospective with a very large GC
dose range, different DM diagnostic criteria, comorbid
conditions that affect insulin sensitivity, and with no de-
scription of the course of hyperglycemia [3,5,9-16]. It is
important to find answers to clinical scenarios in which
GC are used. A common setting is the administration of
high dose (>1 mg/kg/day) GC for one to three months in
a patient without comorbidities and in whom DM can
occur. Obtaining this information would allow appropriate
diagnostic and therapeutic strategies [5,9,17].
With the aim of defining the incidence of secondary
DM, we designed a prospective, longitudinal, observational
study in patients with a recent diagnosis of hematological
diseases without DM and in whom treatment with GC
would be initiated. Secondary end points were to identify
the intensity of hyperglycemia, the moment it develops, its
progression, and the risk factors, possible mechanisms re-
sponsible for the occurrence of hyperglycemia, and the im-
pact of a continuous glucocorticoid regimen (CGC) vs. a
cyclic glucocorticoid regimen (CyGC).
Subjects and methods
Subjects
We studied 35 consecutive patients of the Hematology
Service of the “Dr. José E. Gonzalez” University Hospital.
Approval was obtained from the Institutional Review
Board and all participants signed an informed consent.
Male or female patients between 18 and 80 years of age
with acute lymphoblastic leukemia (ALL) or non-
Hodgkin’s lymphoma (NHL) who needed treatment with
a dose of GC equal to or greater than 1 mg/kg/day of
prednisone were included. Pregnant women, those with
a personal history of DM and a fasting plasma glucose
level ≥5.60 mmol/L at enrollment and use of GC for
more than 7 days in the last two years or the use of
medications that cause secondary DM were excluded.
Study protocol
After baseline blood sampling, patients were started on
GC treatment for their hematological disease. The possi-
bilities were twofold: CGC or CyGC with prednisone. In
CGC, the study period was eight weeks, taking a weekly
blood sample for determination of fasting plasma glucose
and serum insulin. In addition, participants kept a weekly
record of three 2-hour postprandial capillary glucose
determinations. For ALL cases, a prednisone dose of
100 mg/day was used daily only during the first 6 weeks
(CGC). In NHL cases, follow-up was for 12 weeks with a
fasting plasma glucose and serum insulin determinationevery 20 days, at baseline and then before each GC cycle
(CyGC). In addition, participants kept a weekly record of
one fasting and three 2-hour postprandial capillary glucose
determinations. The cycle was 100 mg of prednisone daily
for five days followed by 15 days off. This was repeated five
times. To contrast this with the other group (CGC), the
participants were also evaluated at eight weeks. At this mo-
ment, CGC subjects had received 42 days of GC and were
evaluated 14 days after interruption. Those with CyGC had
received three cycles, with 11 days free from GC.
Diagnostic categories of hyperglycemia
Fasting hyperglycemia was defined as a plasma glucose
≥5.60 mmol/L. Prediabetes and DM were defined as a
fasting plasma glucose ≥5.60 and <7.00 mmol/L and
≥7.00 mmol/L, respectively [1]. A postprandial capillary
glycemia ≥11.10 mmol/L was considered abnormal [18].
Any fasting plasma glucose result ≥5.60 mmol/L was con-
firmed with a new determination. Any postprandial capil-
lary glycemia ≥11.10 mmol/L was confirmed by another
capillary determination. Any participant who developed
prediabetes and DM during the study, was classified as
having DM.
Risk factors for diabetes mellitus
The risk factors considered were age ≥45 years, a body
mass index (BMI) ≥25 kg/m2, a waist-hip ratio (WHR)
≥0.8, hypertension, acanthosis nigricans and a history of
type 2 DM in a first-degree relative.
Measurements
For the measurement of plasma glucose, the glucose
oxidase method (Adiva 1650 Chemistry System, Bayer,
Leverkueusen, Germany: Intraassay CV <2%) was used.
For serum insulin an electrochemiluminescence immuno-
assay (Roche Diagnostics, Indianapolis, IN; Intraassay CV
<2%) was used. Capillary glycemia was determined with
test strips and a glucometer (Accu-Chek Active, Roche
Diagnostics Corp., Basel, Switzerland). The homeostatic
model assessment (HOMA) insulin resistance (IR) and
HOMA β-cell function (β-cell) were calculated as previ-
ously described [19].
Statistical analysis
All results are reported as means ± standard deviation
unless otherwise indicated. We conducted a descriptive
statistical analysis for quantitative variables, measures of
central tendency and dispersion. In the case of quantita-
tive variables, frequencies were obtained. In quantitative
comparative data, we used Student’s t test, paired or un-
paired, depending on the case. For dichotomous variables
we used the X2 test. For the magnitude of association we
used odds ratio. A P≤ 0.05 or an odds ratio different from
1 was considered significant. The statistical analysis was
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Armonk, NY).
Results
Study population
Thirty-five patients were enrolled and 32 (91%) completed
the study. Three participants were excluded, two due to
death because of hematological complications and a third
due to poor protocol compliance. Table 1 shows the base-
line clinical characteristics of the total group and by CGC
and CyGC groups. Mean age was 38.4 years. Fifty-three
percent were women. NHL was the most common dis-
ease. Mean BMI was 27.1 ± 5.7 kg/m2 and 63% had a fam-
ily history of type 2 DM. There were no statistical
differences between groups (CGC vs. CyCG) at baseline.
Development of hyperglycemia and secondary diabetes
mellitus
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ontinuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen;
cute lymphoblastic leukemia; NHL, non-Hodgkin’s lymphoma; GC,
corticoids; BMI, Body-Mass Index; W/H ratio, waist to hip ratio; PAD,
isone accumulative dose; AN, acanthosis nigricans; and DM,
tes mellitus.and prediabetes by fasting glycemia criteria was
34.3% in each category (11 of 32). All cases without
fasting hyperglycemia (10 cases) were on CyGC. The
cumulative dose of prednisone was significantly
higher in those who developed hyperglycemia
(2972 ± 1376 vs. 1500 ± 0 mg, respectively)
(P = 0.002). The cumulative dose of prednisone in
DM cases was 3218 ± 1362 vs. 2727 ± 1410 and
1500 ± 0 mg/day in prediabetes and in the group
without fasting hyperglycemia (P = 0.67 and 0.0008),
respectively. Only one subject developed fasting
hyperglycemia between 8 and 12 weeks with a
glycemia of 6.66 mmol/L.
b) Postprandial capillary glycemia
By week eight, the incidence of postprandial
capillary hyperglycemia was 15.6% (5 out of 32
cases) (Table 2). Three also had a fasting plasma
glycemia ≥7.00 mmol/L. There were eight subjects
with a fasting glycemia ≥7.00 mmol/L without
postprandial hyperglycemia. At 12 weeks, no new
cases of postprandial hyperglycemia occurred. The
cumulative dose of prednisone for cases with and
without postprandial hyperglycemia was not
statistically different.
Characterization of hyperglycemia
Prediabetes occurred in 34.3% (11 out of 32 cases)
(Table 2). Fifty-four percent of the cases occurred in the
first week. DM also occurred in 11 of 32 cases (34.3%).
Five cases occurred between the second and fourth
week (9.25 ± 2.90 mmol/L), and six afterwards (7.37 ±
0.40 mmol/L). Eleven cases had prediabetes without
developing DM. Treatment was not started in any case
and values normalized spontaneously.
Of the 22 participants with fasting hyperglycemia, 15
normalized by the eighth week. The other seven cases
had a fasting glycemia between 5.60 and 7.94 mmol/L
(6.50 ± 0.93 mmol/L). Two belonged to the CGC group
(7.94 and 6.72 mmol/L). Of the other five cases, at week
12, three normalized and two continued with prediabe-
tes. All cases of postprandial hyperglycemia normalized
at 8 weeks.
Risk factors
A multiple logistic regression analysis was performed,
which detected that only the CGC scheme (OR 2.0,
95% CI, 1.29–3.1) was an independent risk factor for
developing DM (P = 0.003). Other risk factors studied
did not show significant differences (Table 3).
CGC vs. CyGC
The incidence of fasting hyperglycemia at eight weeks
was 100% with CGC vs. 50% with CyGC (P = 0.003)
(Table 4). Of these, seven and four had DM, respectively.
Table 2 Incidence and time of occurrence of the different
categories of hyperglycemia at 8 weeks follow-up in all
studied patients (n = 32)
Category Value
Non-hyperglycemic (≤ 5.6 mmol/L)
n (%) 10 (31.3)
Baseline fasting glycemia (mmol/L) 4.7 ± 0.6
Plasma glucose (mmol/L) 4.5 ± 0.8
Cyclic 10
Continuous 0
PAD (mg/patient)1 1500 ± 0
Fasting hyperglycemia (≥5.60 mmol/L)
Incidence, n (%) 22 (68.7)
Baseline fasting glycemia (mmol/L) 4.8 ± 0.7
Plasma glucose (mmol/L) 7.08 ± 3.04
PAD (mg/patient)2 2972 ± 1376
Cyclic 10
Continuous 12
P value (1 vs. 2) 0.002*
Prediabetes (≥5.60- < 7.00 mmol/L)
Incidence, n (%) 11 (34.3)
Baseline fasting glycemia (mmol/L) 4.6 ± 0.9
Plasma glucose (mmol/L)3 6.01 ± 0.35
PAD (mg/patient)3 2727 ± 1410
P value (1 vs. 3) 0.01*
Prediabetes appearance (week), n (%)
First 6 (54.5)
Second to fourth 2 (18.1)
Fifth to eighth 3 (27.3)
DM (fasting glycemia ≥7.00 mmol/L)
Incidence, n (%) 11 (34.3)
Baseline fasting glycemia (mmol/L) 5.1 ± 0.8
Plasma glucose (mmol/L) 8.90 ± 3.63
PAD (mg/patient) 4 3218 ± 1362
P value (1 vs. 4) 0.0008*
P value (3 vs. 4) 0.67
DM occurrence (week), n (%)
First 0 (0)
Second to fourth 5 (45.5)
Fifth to eighth 6 (54.5)
Postprandial hyperglycemia
Incidence, n† (%) 5 (15.6)
Capillary Glycemia (mmol/L) 11.33 ± 0.30
PAD (mg/patient)
Table 2 Incidence and time of occurrence of the different
categories of hyperglycemia at 8 weeks follow-up in all
studied patients (n = 32) (Continued)
Hyperglycemic cases5 2040 ± 1207
Non-hyperglycemic cases6 2600 ± 1351
P value (5 vs. 6) 0.39
All data are reported as total number of subjects and (%) or mean ± SD.
PAD, prednisone accumulative dose; DM, diabetes mellitus GC; Glucocorticoid.
*Significant P value ≤ 0.05.
†Three cases also had a fasting plasma glucose ≥7.00 mmol/L.
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the second and fourth week. All four cases in the CyGC
group occurred after the fourth week. There was no
significant difference in the incidence of postprandial
hyperglycemia between groups (P = 0.62).
Basal insulin, HOMA-IR and ß-cell were not statistically
different between groups (Table 5). The mean values of
serum insulin levels increased during follow-up. When
the two groups were compared, there was no significant
difference. Average baseline insulin, HOMA-IR, and
HOMA ß-cell of the participants with and without DM in
the CGC group compared with the values of the CyGC
group were not statistically different. However, the average
peak value for insulin in both groups (CGC and CyGC)
was statistically significant when cases with and without
DM were compared (P = 0.02 and 0.01, respectively).
Average peak values of insulin between CGC and CyGC
groups showed significant differences (238.21 ± 73.62 vs.
150.71 ± 70.14 pmol/L, respectively; P = 0.002).Discussion
In a noncritically ill adult population, using a high dose of
prednisone (>1 mg/kg/day) for 6 to 12 weeks, in two clas-
sical schemes of GC administration, under close monitor-
ing of fasting and postprandial glycemia, we identified aTable 3 Risk factors associated to glucocorticoid-induced
hyperglycemia
OR 95% CI P*
Age 0.75 0.15 – 3.7 0.73
BMI† 0.33 0.66 – 1.47 0.13
W/H Ratio 0.89 0.134 – 5.88 0.90
AN 0.40 0.48 – 3.34 0.39
DM FH 2.14 0.464 – 9.90 0.33
GC Regimen (CGC vs. CyGC) 2.00 1.29 – 3.1 0.003*
*Significant P value ≤ 0.05.
†BMI = weight in kilograms by the square of the height in meters.
OR, Odds Ratio; CI 95%, 95% Confidence Interval; BMI, Body Mass Index; W/H,
waist-to-hip ratio; AN, acanthosis nigricans; DM FM, diabetes mellitus family
history; GC, glucocorticoid; CGC, continuous glucocorticoid regimen, and
CyGC, Cyclic Glucocorticoid regimen.
Table 4 Incidence and categories of hyperglycemia in
accordance to scheme of GC therapy
Variable CGC
n = 12
CyGC
n = 20
P*
PAD (mg/patient)
8 weeks 4200 1500 -
12 weeks - 2500 -
Fasting hyperglycemia (≥5.60 mmol/L)
Incidence, n (%) 12 (100) 10 (50) 0.003*
Plasma glucose (mmol/L) 8.22 ± 3.79 6.50 ± 0.64 0.16
Prediabetes (≥5.60- < 7.00 mmol/L)
Incidence, n (%) 5 (41.6) 6 (30) 0.51
DM (fasting glycemia ≥7.00 mmol/L)
Incidence, n (%) 7 (58.3) 4 (20) 0.22
Plasma glucose (mmol/L) 9.83 ± 4.39 7.11 ± 0.15 0.26
DM occurrence - week, n (%)
First 0 (0) 0 (0) -
Second to fourth 5 (71.4) 0 (0) -
Fifth to eighth 2 (28.5) 4 (100) -
Postprandial hyperglycemia
Incidence, n (%) 1 (8.3) 4 (20) 0.62
All data are reported in total number of subjects and (%) or mean ± SD.
CGC, continuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen;
PAD, prednisone accumulative dose; DM, diabetes mellitus.
*Significant P value ≤0.05.
Table 5 Insulin, HOMA-IR and HOMA ß-cell values at
baseline and during follow up by GC scheme*
Variable CGC n =12 CyGC n = 20 P ^
Baseline
Insulin (pmol/L) 64.59 ± 17.36 53.48 ± 18.75 0.12
HOMA-IR 2.2 ± 0.79 1.73 ± 0.79 0.11
HOMA (β-cell) 112.8 ± 47.8 113.3 ± 63.2 0.98
Insulin, follow-up week (pmol/L)
1 105.56 ± 66.67 - -
2 125.70 ± 75.01 - -
3 142.37 ± 57.64 106.95 ± 59.73 0.11
4 154.87 ± 88.20 - -
5 156.96 ± 86.81 - -
6 169.46 ± 109.73 125.70 ± 73.62 0.19
8 129.87 ± 68.75 - -
9 - 120.15 ± 70.84 -
12 - 96.53 ± 40.28 -
Insulin (pmol/L) [n]
With DM1 63.20 ± 15.97 61.46 ± 20.14 0.88
Without DM2 66.67 ± 21.32 51.39 ± 18.75 0.15
P value (1 vs. 2) 0.75 0.39 -
HOMA-IR
With DM3 2.20 ± 0.74 2.14 ± 0.96 0.91
Without DM4 2.21 ± 0.94 1.62 ± 0.75 0.17
P value (3 vs.4) 0.99 0.35 -
HOMA- β-cell
With DM5 98.8 ± 21.9 135.3 ± 102 0.36
Without DM6 132 ± 68.9 107 ± 53.1 0.40
p value (5 vs.6) 0.24 0.45 -
MMII† pmol/L(%)
With DM [week]7 145.84(231%) [6] 154.18(251%) [9] 0.76
Without DM [week]8 82.64 (116%) [4] 56.25 (111%) [6] 0.37
p value (7 vs. 8) 0.02* 0.01* -
All data reported as total number of subjects and (%) or mean ± SD.
CGC, continuous glucocorticoid regimen; CyGC, cyclic glucocorticoid regimen;
DM, diabetes mellitus; HOMA-IR, Homeostasis Model Assessment Insulin
Resistance; HOMA ß-cell, Homeostasis Model Assessment Beta Cell Function;
MMII, mean maximum insulin increase.
*Significant P value ≤ 0.05.
p^ continuous vs. cyclic.
HOMA-IR = [Fasting Insulin (μU/ml) x Fasting Glucose (mmol/L)]/22.5.
HOMA- ß-cell = [20 x Fasting Insulin (μU/ml)]/[Fasting Glucose (mmol/L)]-3.5.
†Mean absolute maximum value.
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fasting and postprandial glycemia, a DM incidence of
40.6% was found. For prediabetes, the incidence was
34.3%. The incidence of DM did not increase at 12 weeks.
Unlike other series, in this study fasting glycemia was
more sensitive in identifying DM than postprandial deter-
minations [5,11,12,20]. Only two cases that had DM by
postprandial hyperglycemia did not meet fasting plasma
glucose DM criteria. Series of patients on high doses of GC
have found a DM incidence in the range of our study, be-
tween 12.6% and 52% [11,13-16]. Despite methodological
problems such as: different populations with heteroge-
neous comorbidities, diverse diagnostic methods for DM, a
lack of close monitoring of glycemia and varying patterns
of high doses of GC, the incidence of DM in most of these
studies was between 15% and 25%, less than the incidence
of DM of 40.6% that we found in our study [11,13-16].
This difference can be attributed mainly to the retrospect-
ive design and lack of close systematic monitoring of
fasting and postprandial glycemia. Contrary to our study,
the study with the highest incidence (52%) is a retrospect-
ive series in which all cases of DM were detected solely by
postprandial glycemia [11].
When starting high-dose GC in a subject without DM,
there are two interesting clinical issues for making appro-
priate decisions: the intensity that hyperglycemia canreach and when it may occur. With regard to the intensity,
acute complications of DM have been reported in a few
critically ill cases [14,21-24]. In this study, most of the
time hyperglycemia was not intense, deciding, under close
supervision, not to start management of hyperglycemia,
which allowed recording its evolution. The average fasting
glycemia of patients with DM was 8.89 mmol/L and only
four of 32 patients had a fasting glycemia greater than
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ively and closely evaluated the intensity of hyperglycemia.
The second issue is the time it takes for hyperglycemia to
occur. Of the 13 cases of DM, none occurred in the first
or after the eighth week, and half appeared between the
second and fourth week. Therefore, it is advisable to
search for it during the second, fourth and sixth week of
exposure to high doses of GC. This finding is consistent
with the results of other authors that have also identified
most cases of DM in early stages of exposure to GC
[12,14,15]. Recently, a clinical practice guideline on the
management of hyperglycemia in hospitalized patients,
suggested that monitoring of glycemia in individuals with-
out diabetes exposed to GC can be interrupted if glycemia
is less than 7.78 mmol/L for a period of at least 24 to
48 hours [25]. Our results in noncritically ill patients show
that hyperglycemia occurs after the first week or even until
the eighth week of exposure to GC, coinciding with find-
ings in other retrospective series [12,14,15]. It is likely that
other comorbidities that are present in hospitalized
patients alter the action or secretion of insulin and antici-
pate the onset of hyperglycemia.
Another question that has not been carefully evaluated
in previous studies is the course of hyperglycemia. In
this study, two-thirds of subjects with prediabetes or
DM normalized spontaneously by the eighth week. The
rest, at 12 weeks, showed normal glycemia or were in
the range of prediabetes. This spontaneous remission in
the majority of the participants could be attributed to
the absence of other comorbidities, which might impair
insulin secretion or action. Many cases of severe hyper-
glycemia related to GC use, occurred in subjects with an
aggregated acute disease [14,23,24].
Some authors have proposed that in individuals with a
prediabetes state, GC could precipitate the onset of DM
[2,5,6]. In our study, mean basal serum insulin and
HOMA-IR were not different between participants with
CGC or CyGC or when comparing subjects with and
without DM. These findings suggest that at the beginning
there was no difference in insulin resistance between the
groups. However, in participants on CGC and CyGC who
developed DM there was a significant increase in insulin
secretion compared with those who did not. This finding
suggests that the primary mechanism involved in the on-
set of DM is most likely, increased insulin resistance, asso-
ciated to a limited compensatory ability of the pancreas.
Conclusion
In a noncritically ill population, without other comor-
bidities, the use of high doses of GC for two to three
months, as a CGC or CyGC dose, caused a high incidence
of DM with non-severe hyperglycemia, most often with
CGC, which appeared after the second week of GC treat-
ment and resolved spontaneously without treatment in thenext six weeks. Even though these results reflect glucose
behavior in two specific hematological disorders, the clin-
ical and therapeutic characteristics of our participants, who
were otherwise healthy, could represent the clinical setting
of many patients of other medical areas that might require
high doses of GC for six to twelve weeks. It would be useful
to perform prospective studies in other clinical situations
that use GC, such as patients with multiple comorbidities,
long-term low dose GC, or in critically ill patients.
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